Future cardiology最新文献_第2页

Uni-leaflet mitral valve in adults: a systematic review of case reports and case series. 成人单叶二尖瓣：病例报告和病例系列的系统回顾。

IF 1

Future cardiology Pub Date : 2026-04-16 DOI: 10.1080/14796678.2026.2659088

Martina Mookadam, Safiyya A Mookadam, Michael Morris, Sandip Pradhan, Farouk Mookadam

{"title":"Uni-leaflet mitral valve in adults: a systematic review of case reports and case series.","authors":"Martina Mookadam, Safiyya A Mookadam, Michael Morris, Sandip Pradhan, Farouk Mookadam","doi":"10.1080/14796678.2026.2659088","DOIUrl":"https://doi.org/10.1080/14796678.2026.2659088","url":null,"abstract":"Introduction: Uni-leaflet mitral valve (ULMV) is a rare congenital anomaly historically considered incompatible with long-term survival, yet increasing reports describe diagnosis in adulthood. We conducted a systematic review to characterize clinical presentation, anatomy, imaging findings, management, and outcomes in adults with ULMV.Methods: Following PRISMA guidelines, major databases were searched from 1960 through January 2024. Eligible studies reported adult patients with confirmed ULMV. Data were extracted on demographics, valve morphology, symptoms, associated anomalies, imaging modalities, interventions, and outcomes.Results: Thirty-six publications comprising 40 adult patients met inclusion criteria. Mean age at diagnosis was 50.5 years, with female predominance. Posterior leaflet hypoplasia or agenesis accounted for 97.5% of cases. Most patients were symptomatic, commonly with dyspnea or heart failure, and over half had moderate or greater mitral regurgitation. Atrial fibrillation, atrial septal defects, and aortic valve abnormalities were frequent comorbidities. Transthoracic echocardiography was used universally, with transesophageal and three-dimensional imaging providing incremental anatomical detail. Approximately one-third underwent mitral valve repair or replacement, with generally favorable outcomes.Conclusions: Adult ULMV demonstrates marked clinical and anatomical heterogeneity and may represent a developmental spectrum rather than a single entity. Standardized definitions and prospective registries are needed to improve risk stratification and guide management.Protocol registration: http://www.crd.york.ac.uk/prospero identifier is CRD420251083213.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in predicting and improving outcomes in patients undergoing transcatheter tricuspid valve intervention. 预测和改善经导管三尖瓣介入治疗患者预后的最新进展。

IF 1

Future cardiology Pub Date : 2026-04-14 DOI: 10.1080/14796678.2026.2652420

Lisa Serafini, Alessandra Ricci, Elisa Pezzola, Michele Legati, Francesca Capasso, Francesca Pugno Vanoni, Oliviana Geavlete, Ovidiu Chioncel, Marco Metra, Marianna Adamo

{"title":"Recent advances in predicting and improving outcomes in patients undergoing transcatheter tricuspid valve intervention.","authors":"Lisa Serafini, Alessandra Ricci, Elisa Pezzola, Michele Legati, Francesca Capasso, Francesca Pugno Vanoni, Oliviana Geavlete, Ovidiu Chioncel, Marco Metra, Marianna Adamo","doi":"10.1080/14796678.2026.2652420","DOIUrl":"https://doi.org/10.1080/14796678.2026.2652420","url":null,"abstract":"Tricuspid regurgitation (TR) has long been underestimated, traditionally viewed as a benign condition, yet contemporary evidence demonstrates its high prevalence and substantial adverse prognostic implications. Medical therapy remains limited, and although surgery has historically been the standard of care, many patients are referred at advanced stages, contributing to poor operative outcomes. Transcatheter tricuspid valve interventions (TTVI) have emerged as a valuable therapeutic option, showing consistent improvements in symptoms, quality of life (QoL), and heart failure hospitalizations (HFH), although a definitive survival benefit has not yet been established. Optimal management requires a comprehensive, multiparametric, and multidisciplinary approach. Key elements include careful assessment of TR etiology, clinical status, right heart failure stage, multimodality imaging, risk scores, and invasive hemodynamics. Integrating these factors enables appropriate patient selection, individualized treatment strategies, and avoidance of futile procedures. Ultimately, decisions regarding intervention and device choice should be guided by a dedicated multidisciplinary Heart Team within a specialized Heart Valve Center.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-13"},"PeriodicalIF":1.0,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reducing adverse events after percutaneous coronary intervention: the benefits of a personalized approach to dual antiplatelet therapy. 减少经皮冠状动脉介入治疗后的不良事件：双重抗血小板治疗的个性化方法的益处。

IF 1

Future cardiology Pub Date : 2026-03-30 DOI: 10.1080/14796678.2026.2649866

Felice Gragnano, Vincenzo De Sio, Giuseppe Verde, Paolo Calabrò

引用次数: 0

Predicting adverse outcomes after cardiac surgery and structural interventions: the role of right ventricular function. 预测心脏手术和结构性干预后的不良后果：右心室功能的作用。

IF 1

Future cardiology Pub Date : 2026-03-25 DOI: 10.1080/14796678.2026.2643096

Eszter Pál, Veronika Párkányi, Tímea Katalin Turschl, Alexandra Fábián, Andrea Ferencz, Márton Tokodi, Máté Tolvaj, Andrea Nagy, Attila Kovács, Béla Merkely, Bálint Károly Lakatos, Zsuzsanna Ladányi

{"title":"Predicting adverse outcomes after cardiac surgery and structural interventions: the role of right ventricular function.","authors":"Eszter Pál, Veronika Párkányi, Tímea Katalin Turschl, Alexandra Fábián, Andrea Ferencz, Márton Tokodi, Máté Tolvaj, Andrea Nagy, Attila Kovács, Béla Merkely, Bálint Károly Lakatos, Zsuzsanna Ladányi","doi":"10.1080/14796678.2026.2643096","DOIUrl":"https://doi.org/10.1080/14796678.2026.2643096","url":null,"abstract":"Right ventricular (RV) function is a major determinant of clinical outcomes in patients undergoing cardiac surgery and transcatheter interventions. Although left ventricular morphology and function have been the traditional focus of preprocedural assessment, RV dysfunction is now recognized as an important predictor of morbidity and mortality. Therefore, inclusion of RV-related parameters in preprocedural risk assessment is on the rise. This review summarizes current evidence on the role of RV function in various cardiac diseases that require surgery or interventions. Conventional two-dimensional echocardiographic parameters, such as tricuspid annular plane systolic excursion, RV fractional area change, and peak systolic tissue Doppler velocity, provide limited information due to the complex RV geometry. Advanced imaging techniques, including speckle-tracking, three-dimensional echocardiography, and cardiac magnetic resonance imaging, enable more accurate quantification of RV volumes, ejection fraction, strain, RV motion components and RV-pulmonary artery coupling, and have demonstrated superior prognostic value. Therefore, a comprehensive assessment of RV function using advanced imaging techniques should be incorporated into routine clinical practice to improve risk stratification and preprocedural planning before cardiac surgery and transcatheter interventions. However, it is necessary to standardize imaging protocols and define validated reference thresholds to support the clinical implementation of these state-of-the-art parameters.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-13"},"PeriodicalIF":1.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147511326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction - ARIISE study design. 脂肪组织源性间充质细胞治疗非缺血性心力衰竭伴射血分数降低- ARIISE研究设计。

IF 1

Future cardiology Pub Date : 2026-03-25 DOI: 10.1080/14796678.2026.2647879

Nadia Chaaban, Jens Kastrup, Kasper Rossing, Morten Schou, Jens Hove, Pernille Buch, Annette Ekblond, Ellen Mønsted Johansen, Morten Juhl Nørgaard, Lisbeth Drozd Højgaard, Abbas Ali Qayyum

{"title":"Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction - ARIISE study design.","authors":"Nadia Chaaban, Jens Kastrup, Kasper Rossing, Morten Schou, Jens Hove, Pernille Buch, Annette Ekblond, Ellen Mønsted Johansen, Morten Juhl Nørgaard, Lisbeth Drozd Højgaard, Abbas Ali Qayyum","doi":"10.1080/14796678.2026.2647879","DOIUrl":"https://doi.org/10.1080/14796678.2026.2647879","url":null,"abstract":"Heart failure (HF) remains a major clinical and healthcare challenge with high morbidity, mortality, and impaired quality of life (QOL). Approximately 30-40% of HF cases in the western world are of nonischemic heart failure (NIHF) origin; yet, regenerative therapies are lacking. Evidence suggests that systemic inflammation contributes to disease progression in NIHF, highlighting immunomodulation as a potential therapeutic target. Mesenchymal stromal cells (MSCs) possess regenerative and immunomodulatory properties, with adipose tissue derived stromal cells (ASCs) emerging as particularly promising. ARIISE is a Danish, multicenter, randomized, double-blinded, placebo-controlled study evaluating the efficacy and safety of intravenous allogeneic ASC therapy (C2C_ASC110) in patients with NIHF and reduced left ventricular ejection fraction (LVEF ≤ 45%). Ninety patients will be randomized to receive either C2C_ASC110 or placebo dimethyl sulfoxide (DMSO) (Cryostor®) intravenously twice 1 month apart, in addition to optimal guideline-directed medical therapy. The primary endpoint is a change in LVEF at 6-month follow-up after second ASC/placebo infusion. Secondary endpoints include other echocardiographic measurements, functional capacity, biomarkers, quality of life (QOL), and safety outcomes. If successful, ARIISE may establish clinical evidence for intravenous ASC therapy as a safe, feasible, and effective regenerative treatment for patients with NIHF.Clinical trial registration: EU CT number: 2025-520837-22-00, UTN number: U1111-1315-7011, Clinicaltrials.gov number: NCT06840275.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147511267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Omega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis. Omega-3多不饱和脂肪酸暴露与透析心血管结局：系统回顾和荟萃分析。

IF 1

Future cardiology Pub Date : 2026-03-18 DOI: 10.1080/14796678.2026.2645005

Arveen Shokravi, Sohat Sharma, Rishav Singh, Jayant Seth, G B John Mancini

{"title":"Omega-3 polyunsaturated fatty acid exposure and cardiovascular outcomes in dialysis: a systematic review and meta-analysis.","authors":"Arveen Shokravi, Sohat Sharma, Rishav Singh, Jayant Seth, G B John Mancini","doi":"10.1080/14796678.2026.2645005","DOIUrl":"https://doi.org/10.1080/14796678.2026.2645005","url":null,"abstract":"Background: Patients with dialysis-dependent chronic kidney disease (CKD) have a high cardiovascular burden, prompting interest in fish oils or long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) as potential risk-reducing therapies in this population.Methods: We conducted a systematic review and meta-analysis of studies in adults receiving dialysis that assessed associations between n-3 PUFA supplementation, baseline levels, or dietary intake and CV outcomes, or all-cause mortality. Hazard ratios (HRs) were pooled using random-effects models.Results: Twelve studies met inclusion criteria. In hemodialysis-dependent CKD, fish oil supplementation lowered cardiovascular events by 44% (HR 0.56; 95% CI 0.46-0.68) and myocardial infarction by 48% (HR 0.52; 95% CI 0.34-0.78). Higher baseline n-3 PUFA levels were associated with a 31% reduction in all-cause mortality (HR 0.69; 95% CI 0.54-0.88). Higher dietary n-3 PUFA intake showed a non-significant trend toward lower all-cause mortality (HR 0.92; 95% CI 0.79-1.08).Conclusion: In dialysis-dependent CKD, higher n-3 PUFA exposure through fish oil supplementation or higher baseline levels was associated with fewer cardiovascular events and all-cause mortality. Appropriately dosed n-3 PUFA supplementation represents a promising cardiovascular risk reduction strategy in dialysis-dependent CKD, although confirmatory randomized trials are warranted.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-8"},"PeriodicalIF":1.0,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping and evaluation of global and country-specific cardiovascular disease risk prediction models. 绘制和评估全球和特定国家心血管疾病风险预测模型。

IF 1

Future cardiology Pub Date : 2026-03-17 DOI: 10.1080/14796678.2026.2645012

Samina Akhtar, Zainab Samad, Gerald S Bloomfield, Salim S Virani, Aysha Almas

{"title":"Mapping and evaluation of global and country-specific cardiovascular disease risk prediction models.","authors":"Samina Akhtar, Zainab Samad, Gerald S Bloomfield, Salim S Virani, Aysha Almas","doi":"10.1080/14796678.2026.2645012","DOIUrl":"10.1080/14796678.2026.2645012","url":null,"abstract":"Cardiovascular diseases (CVDs) remain a leading cause of global morbidity and mortality, requiring precise risk prediction models for effective prevention and management. This review maps and evaluates globally utilized and country-specific CVD risk prediction models, including the Framingham Risk Score, Pooled Cohort Equations, PREVENT, WHO/ISH Risk Charts, INTERHEART, and SCORE2. A structured literature search was conducted using PubMed and Google Scholar, from which 30 relevant studies were selected. Most of the models integrate traditional risk factors such as age, sex, blood pressure, cholesterol, and smoking status to estimate CVD risk. While these models demonstrate moderate to good discrimination (C-statistics ranging from 0.66 to 0.80) and validation, their applicability varies across populations, with concerns about overestimation or underestimation in non-original cohorts. Notably, the WHO/ISH and Globorisk models address global diversity by incorporating regional calibrations, making them suitable for low- and middle-income countries. Similarly, the country-specific risk scores outperform global models due to their incorporation of local socio-demographics. Limitations persist across existing models, including the underrepresentation of younger individuals, ethnic minorities, and the exclusion of emerging risk factors. Future efforts must prioritize the development of locally validated, population-specific models to support equitable and effective CVD risk assessment and prevention.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-10"},"PeriodicalIF":1.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13102548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-myocardial infarction complications in patients with inflammatory bowel disease: a retrospective cohort study using the National Inpatient Sample (2016-2022). 炎症性肠病患者心肌梗死后并发症：一项使用全国住院患者样本（2016-2022）的回顾性队列研究

IF 1

Future cardiology Pub Date : 2026-03-02 DOI: 10.1080/14796678.2026.2639403

Omar Alkasabrah, Siddharth Pravin Agrawal, Abdullah Hafeez, Ahmed Farid Gadelmawla, Yasmine Adel Mohammed, Marina Takawy, Sameeha Ibrahim, Dhruvi K Joshi, Hritvik Jain, Wilbert S Aronow

{"title":"Post-myocardial infarction complications in patients with inflammatory bowel disease: a retrospective cohort study using the National Inpatient Sample (2016-2022).","authors":"Omar Alkasabrah, Siddharth Pravin Agrawal, Abdullah Hafeez, Ahmed Farid Gadelmawla, Yasmine Adel Mohammed, Marina Takawy, Sameeha Ibrahim, Dhruvi K Joshi, Hritvik Jain, Wilbert S Aronow","doi":"10.1080/14796678.2026.2639403","DOIUrl":"https://doi.org/10.1080/14796678.2026.2639403","url":null,"abstract":"Background: Inflammatory bowel disease (IBD) is associated with systemic inflammation and increased cardiovascular risk, but its impact on in-hospital outcomes after acute myocardial infarction (MI) remains unclear.Methods: We conducted a retrospective cohort study using the National Inpatient Sample (2016-2022) to identify hospitalizations for acute MI and compared outcomes between patients with and without IBD. Multivariate logistic regression was used to evaluate the association between IBD and post-MI complications. Associations were summarized as adjusted odds ratios (aORs) with 95% confidence intervals (CIs).Results: Among 1,456,940 MI hospitalizations, 7,430 had IBD. After adjustment, IBD was associated with higher odds of mortality (aOR 3.32, 95% CI 3.18-3.47; p < 0.0001), left ventricular rupture (aOR 4.46, 95% CI 3.16-6.28; p < 0.0001), left ventricular aneurysm (aOR 1.93, 95% CI 1.61-2.31; p < 0.0001), acute mitral regurgitation (aOR 9.80, 95% CI 6.81-14.10; p < 0.0001), and stent restenosis (aOR 1.16, 95% CI 1.07-1.26; p = 0.0002). IBD was also associated with longer hospital stay (coefficient 2.13 days, 95% CI 2.03-2.23; p < 0.0001) and higher total hospital charges.Conclusion: IBD was associated with worse in-hospital outcomes and higher resource utilization after MI in this nationwide hospitalization-level analysis.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.0,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Invasive versus conservative strategy in older adults ≥70 years of age with non-ST-segment-elevation myocardial infarction: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. ≥70岁非st段抬高型心肌梗死老年人的侵入性与保守性治疗策略：一项grade评价的系统评价和随机对照试验的荟萃分析。

IF 1

Future cardiology Pub Date : 2026-03-01 Epub Date: 2026-02-04 DOI: 10.1080/14796678.2026.2618448

Ubaid Khan, Junaid Ali, Muhammad Haris Khan, Mahmoud Shaaban Abdelgalil, Zuhair Majeed, Muhammad Abdullah Naveed, Ahmed Mazen Amin, Anum Nawaz, Mohamed Abuelazm, Mustafa Turkmani, Muhammad Aamir, Apurva V Vyas, Sourbha Dani

{"title":"Invasive versus conservative strategy in older adults ≥70 years of age with non-ST-segment-elevation myocardial infarction: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.","authors":"Ubaid Khan, Junaid Ali, Muhammad Haris Khan, Mahmoud Shaaban Abdelgalil, Zuhair Majeed, Muhammad Abdullah Naveed, Ahmed Mazen Amin, Anum Nawaz, Mohamed Abuelazm, Mustafa Turkmani, Muhammad Aamir, Apurva V Vyas, Sourbha Dani","doi":"10.1080/14796678.2026.2618448","DOIUrl":"10.1080/14796678.2026.2618448","url":null,"abstract":"Background: Older adults with Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) are often undertreated invasively due to concerns about risks and comorbidities, despite potential benefits. Their limited inclusion in clinical trials leaves a gap in evidence-based management. This meta-analysis compared invasive versus conservative strategies in elderly NSTEMI patients.Methods: A systematic search was conducted across PubMed, CENTRAL, Web of Science, Scopus, and Embase through December 2024. Pooled results were reported using risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes with 95% confidence intervals (CI).Results: A total of 11 randomized controlled trials involving 4114 patients were included. Invasive treatment significantly reduced the composite of all-cause mortality and non-fatal MI (RR: 0.82; 95% CI: 0.68-0.99; p = 0.04) and MI alone (RR: 0.68; 95% CI: 0.56-0.84; p = 0.0003). There was no significant difference in all-cause mortality (RR: 1.04; 95% CI: 0.92-1.16; p = 0.55) or cardiovascular death (RR: 0.96; 95% CI: 0.78-1.18; P = 0.67). Invasive strategy significantly lowered the need for revascularization (RR: 0.29; 95% CI: 0.21-0.40; p < 0.0001).Conclusion: In NSTEMI patients aged ≥70, invasive management reduces the risk of MI and revascularization without increasing mortality risk. More elderly-focused trials are warranted.Protocol registration: https://www.crd.york.ac.uk/prospero identifier is CRD42025633157.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"285-299"},"PeriodicalIF":1.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13020887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving landscape of guideline-directed medical therapy in heart failure with improved ejection fraction. 改善射血分数的心力衰竭药物治疗的发展前景

IF 1

Future cardiology Pub Date : 2026-03-01 Epub Date: 2026-02-04 DOI: 10.1080/14796678.2026.2625121

Nandan Kodur, W H Wilson Tang

引用次数: 0